Drug recall · August 16, 2017
Glipizide Extended-Release Tablets recall
Why: Failed Moisture Limits: out of specification test results for water content obtained during stability testing.
Class III: unlikely to cause harm, but breaks the rules (for example a labeling error).
The recall
- Product
Glipizide Extended-Release Tablets (anti-diabetic agent), 5 mg, packaged in 30-unit dose blister pack per carton, Rx only, Mfd for: Watson Laboratories, Inc., Corona, CA 92880, Mfd by: Patheon Pharmaceuticals, Inc., Cincinnati, OH 43215, NDC 0591-0844-15
- Lots / codes
Lot # 3138405A, Exp 8/2017
- Quantity
- 2,880 cartons (30 unit dose blister pack per carton)
- Company
- Teva Pharmaceuticals USA, North Wales, PA
- Distribution
- Product distributed to OH, IL, PA, MI, VA and CT
- Initiated
- August 2, 2017 · Voluntary: Firm initiated
- Classified
- August 8, 2017
- Reported
- August 16, 2017
- Ended
- February 28, 2018
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Glipizide
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.